公开(公告)号：EP2579854B2

公开(公告)日：2018-07-04

申请号：EP11727080.1

申请日：2011-06-09

申请人： AbbVie Bahamas Ltd.

发明人： LIEPOLD, Bernd ,  JUNG, Tina ,  HOLIG, Peter ,  SCHROEDER, Rudolf ,  SEVER, Nancy E. ,  LAFOUNTAINE, Justin ,  SINCLAIR, Brent D. ,  GAO, Yi ,  WU, Jianwei ,  ERICKSON, Bryan K. ,  KULLMANN, Simon ,  WESTEDT, Ulrich ,  PAULI, Mirko ,  HEITERMANN, Tanja ,  KOENIG, Renato ,  THIEL, Madlen ,  WOEHRLE, Gerd

IPC分类号： A61K9/14 ,  A61K9/16 ,  A61K9/20 ,  A61K31/4025

CPC分类号： A61K31/4025 ,  A61K9/146 ,  A61K9/1617 ,  A61K9/1635 ,  A61K9/1694 ,  A61K9/2027 ,  A61K9/2054 ,  A61K31/00

摘要： The present invention features solid compositions comprising Compound I A , I B , I C or I D , or a pharmaceutically acceptable salt thereof, in an amorphous form. Such compositions are useful for treating HCV infection. In one embodiment, Compound I A , I B , I C or I D , or a pharmaceutically acceptable salt thereof, is formulated in an amorphous solid dispersion which comprises a pharmaceutically acceptable hydrophilic polymer and preferably a pharmaceutically acceptable surfactant.

公开(公告)号：EP2579854B1

公开(公告)日：2015-07-15

申请号：EP11727080.1

申请日：2011-06-09

申请人： AbbVie Bahamas Ltd.

发明人： LIEPOLD, Bernd ,  JUNG, Tina ,  HOLIG, Peter ,  SCHROEDER, Rudolf ,  SEVER, Nancy E. ,  LAFOUNTAINE, Justin ,  SINCLAIR, Brent D. ,  GAO, Yi ,  WU, Jianwei ,  ERICKSON, Bryan K. ,  KULLMANN, Simon ,  WESTEDT, Ulrich ,  PAULI, Mirko ,  HEITERMANN, Tanja ,  KOENIG, Renato ,  THIEL, Madlen ,  WOEHRLE, Gerd

IPC分类号： A61K9/14 ,  A61K9/16 ,  A61K9/20 ,  A61K31/4025

CPC分类号： A61K31/4025 ,  A61K9/146 ,  A61K9/1617 ,  A61K9/1635 ,  A61K9/1694 ,  A61K9/2027 ,  A61K9/2054 ,  A61K31/00

摘要： The present invention features solid compositions comprising Compound I A , I B , I C or I D , or a pharmaceutically acceptable salt thereof, in an amorphous form. Such compositions are useful for treating HCV infection. In one embodiment, Compound I A , I B , I C or I D , or a pharmaceutically acceptable salt thereof, is formulated in an amorphous solid dispersion which comprises a pharmaceutically acceptable hydrophilic polymer and preferably a pharmaceutically acceptable surfactant.